# Interdisciplinary Tumor Boards and Clinicopathologic Conferences ## Introduction Interdisciplinary tumor boards (ITBs) and clinicopathologic conferences (CPCs) represent the cornerstone of collaborative cancer care. Tumor boards bring together specialists from surgery, medical oncology, radiation oncology, pathology, radiology, and other disciplines to review individual patient cases and formulate consensus treatment recommendations. The pathologist plays a central role in these conferences, providing the tissue-based diagnosis that anchors clinical decision-making. Evidence consistently demonstrates that multidisciplinary review improves diagnostic accuracy, changes management in **20-50% of cases** presented, and is associated with improved patient outcomes. ## Structure and Organization of Tumor Boards ### Types of Multidisciplinary Conferences **Disease-specific tumor boards** focus on a single organ system, such as breast, thoracic, gastrointestinal, genitourinary, or head and neck. **General tumor boards** review cases across multiple organ systems and are common in smaller institutions. **Molecular tumor boards** focus on genomic and molecular findings to guide targeted therapy and clinical trial enrollment. **Clinicopathologic conferences (CPCs)** are educational case presentations correlating clinical, radiologic, and pathologic findings, often featuring unknown cases for diagnostic discussion. ### Core Participants The **pathologist** presents the histologic diagnosis, biomarker results, and relevant differential diagnoses. The **radiologist** reviews imaging findings, staging studies, and image-guided biopsy correlation. The **surgeon** discusses surgical options, resectability, and operative findings. The **medical oncologist** addresses systemic therapy options, eligibility for clinical trials, and molecular profiling results. The **radiation oncologist** presents radiation treatment planning and indications. Additional specialists including genetics counselors, palliative care, social work, and nurse navigators participate as indicated. ### Conference Logistics Meetings are regularly scheduled (typically weekly) with a structured agenda and advance case submission. Cases are selected based on complexity, discordant findings, or need for multidisciplinary input. **Prospective review** (before treatment initiation) is more impactful than retrospective review. Documentation of recommendations in the medical record is essential for continuity of care. ![Photograph of a multidisciplinary tumor board session with pathology slides displayed alongside radiology imaging on a split-screen conference setup](tumor-board-conference-room.jpg) ## The Pathologist's Role in Tumor Boards ### Case Preparation All **histologic material** including original slides, re-cuts, and ancillary studies should be reviewed before the conference. Representative microscopic images at relevant magnifications are prepared for projection. Key pathologic findings including tumor type, grade, stage, margin status, and biomarker results are summarized. Areas of diagnostic uncertainty or features requiring clinical correlation are identified. ### Presenting the Pathologic Findings The presentation begins with the **specimen type** and the final diagnosis. Findings that directly impact staging and treatment are highlighted, including lymphovascular invasion, perineural invasion, margin positivity, and lymph node status. **Immunohistochemistry and molecular results** are presented with interpretation and clinical relevance. Any discordance between biopsy and resection diagnoses is addressed. The pathologist should be prepared to discuss the differential diagnosis and the evidence supporting the rendered interpretation. ### Responding to Clinical Questions Clinicians frequently ask questions that require real-time pathologic correlation. Common questions include adequacy of margins, significance of incidental findings, need for additional molecular testing, and pathologic response to neoadjuvant therapy. The pathologist should be prepared to **re-examine slides during the conference** if digital slide viewing is available. When a question cannot be answered immediately, a follow-up timeline should be committed to. ### Impact on Diagnosis and Management Tumor board review leads to a **change in diagnosis** in approximately 5-10% of cases. Changes in management occur in **20-50% of cases**, depending on the complexity of the population reviewed. Discordant pathologic interpretations are identified and resolved, reducing diagnostic error. Additional ancillary testing is recommended that may not have been initially considered. ## Clinicopathologic Conferences ### Educational CPCs The traditional format presents a clinical case with progressive disclosure, followed by pathologic findings. The discussant formulates a differential diagnosis based on clinical and radiologic data before the pathology is revealed. This format emphasizes **clinical reasoning, diagnostic integration**, and the correlation between clinical presentation and tissue findings. Published CPCs (such as the NEJM Case Records of the Massachusetts General Hospital) serve as enduring educational resources. ### Morbidity and Mortality (M&M) Conferences M&M conferences review cases with unexpected outcomes, complications, or diagnostic errors. The focus is on **systems-based analysis** rather than individual blame. Pathologic findings may reveal discrepancies between clinical and pathologic diagnoses. Root cause analysis identifies process improvements to prevent recurrence. ### Autopsy Conferences Autopsy conferences correlate clinical diagnoses with autopsy findings. Autopsy discrepancy rates remain significant, with **major unexpected findings** identified in 10-25% of autopsies. These conferences provide invaluable feedback to clinical teams and reinforce the value of tissue-based diagnosis. They also serve as an educational opportunity for residents in both pathology and clinical specialties. ![Presentation slide format showing side-by-side correlation of CT imaging and gross pathology specimen from a pancreatic cancer resection discussed at tumor board](radiology-pathology-correlation-slide.jpg) ## Quality Metrics and Outcomes ### Measuring Tumor Board Effectiveness **Case volume** tracking includes the number and percentage of cancer cases reviewed before treatment initiation. **Management changes** are documented by frequency and type of treatment plan modifications resulting from tumor board discussion. **Diagnostic revisions** record instances where pathologic diagnosis was changed after multidisciplinary review. **Guideline concordance** assesses whether treatment recommendations align with NCCN or institutional guidelines. **Time to treatment** measures the interval from diagnosis to initiation of therapy. ### Accreditation Requirements The **Commission on Cancer (CoC)** requires prospective multidisciplinary cancer case review. A minimum percentage of newly diagnosed cancer cases must be presented at tumor board. Documentation of tumor board recommendations in the patient record is mandated. Annual reporting of cancer conference activity is required for accreditation. ### Evidence for Improved Outcomes Studies demonstrate that tumor board review is associated with improved adherence to evidence-based guidelines. Patients discussed at tumor boards have higher rates of appropriate staging workups. Retrospective analyses suggest improved survival in selected tumor types when managed through multidisciplinary review. Standardization of care reduces unwarranted variation in treatment approaches. ## Challenges and Solutions ### Common Barriers **Time constraints** with large case volumes may limit discussion depth, making prioritization criteria essential. **Attendance inconsistency** among key specialists reduces the value of the conference. **Documentation gaps** occur when recommendations discussed verbally are not recorded in the medical record. **Case selection bias** may mean only complex cases are presented, missing opportunities to identify errors in straightforward cases. ### Optimizing Conference Effectiveness Implementing **structured case presentation templates** ensures consistency and completeness. A designated coordinator should be assigned for case submission, agenda preparation, and documentation. A **standardized recommendation form** should be scanned or entered into the EHR. Attendance and participation metrics should be recorded and tracked for quality reporting. Case presentations should be limited to those with genuine multidisciplinary questions to maximize discussion time. ### Virtual and Hybrid Formats Virtual tumor boards expanded rapidly during the COVID-19 pandemic and have persisted as a permanent option. Digital pathology and WSI enable high-quality remote slide review during virtual conferences. Hybrid formats allow remote participation while maintaining in-person interaction. Screen-sharing of annotated slides, imaging, and electronic medical records supports effective remote discussion. ![Screenshot of a virtual tumor board session using a video conferencing platform with pathology images shared on screen and participant video feeds visible](virtual-tumor-board-session.jpg) ## Emerging Directions ### Molecular Tumor Boards Dedicated conferences review **next-generation sequencing (NGS)** results and identify actionable mutations. Participants include molecular pathologists, bioinformaticians, clinical geneticists, and medical oncologists. Patients are matched with appropriate targeted therapies or clinical trials based on genomic profiling. Molecular tumor boards represent the intersection of precision medicine and multidisciplinary cancer care. ### Artificial Intelligence Support AI tools can pre-screen cases, flag discordant findings, and suggest relevant literature. Automated extraction of pathology and radiology data can streamline case preparation. Natural language processing of pathology reports can identify cases meeting tumor board selection criteria. AI-assisted image analysis can highlight regions of interest for conference discussion. ## Clinical Pearls Tumor board review changes management in 20-50% of presented cases, and prospective review before treatment initiation provides the greatest clinical impact. The pathologist must prepare thoroughly for tumor boards, including review of all histologic material, ancillary studies, and prior pathology, as diagnostic revisions occur in 5-10% of reviewed cases. Documentation of tumor board recommendations in the medical record is not optional; it is required for Commission on Cancer accreditation and essential for continuity of care. Virtual and hybrid tumor board formats are effective and expand access to multidisciplinary expertise, but require investment in digital pathology infrastructure and standardized presentation workflows. ## References 1. Lamb BW, Brown KF, Nagpal K, et al. Quality of care management decisions by multidisciplinary cancer teams: a systematic review. *Annals of Surgical Oncology*. 2011;18(8):2116-2125. 2. Keating NL, Landrum MB, Lamont EB, et al. Tumor boards and the quality of cancer care. *Journal of the National Cancer Institute*. 2013;105(2):113-121. 3. Pillay B, Wootten AC, Crowe H, et al. The impact of multidisciplinary team meetings on patient assessment, management, and outcomes in oncology settings: a systematic review of the literature. *Cancer Treatment Reviews*. 2016;42:56-72. 4. El Saghir NS, Keating NL, Carlson RW, et al. Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide. *American Society of Clinical Oncology Educational Book*. 2014;34:e461-e466.